ABSTRACT The alveolar accumulation of protein and angiotensin converting enzyme activity was compared with the development of right ventricular hypertrophy in male rats after different periods of monocrotaline exposure. Total doses of monocrotaline were varied by dividing the animals into three groups in which ingestion was limited to three, seven, and 15 days. These groups were studied 21 days after the start of monocrotaline exposure and compared with a group treated continuously for 28 days. The total lung weight increased after three or more days of treatment, while after seven days there was significant alveolar accumulation of protein, which was paralleled by an increase in angiotensin converting enzyme activity in alveolar lavage fluid. Identical changes also occurred after 15 and 28 days of exposure to monocrotaline. Lung angiotensin converting enzyme activity was decreased after three days' ingestion of monocrotaline and did not alter further with longer periods of exposure. None of these effects of monocrotaline in the three and seven day treatment groups was associated with right ventricular hypertrophy, which occurred only in animals treated for 15 or more days. The effects of monocrotaline ingestion on the lung were dose related and had no causal relationship to the development of right ventricular hypertrophy.
Exposure to monocrotaline produces acute endothelial injury and the later development of pulmonary hypertension and cor pulmonale in the rat and has been used as a model for studying the pathophysiology of pulmonary vascular disease occurring in man.'-A single subcutaneous dose of monocrotaline (40-105 mg/kg) will cause alveolar wall interstitial oedema and structural changes in endothelial cells within 24 hours, and a microvascular protein leak that is detectable three days after administration.45 A causal link has been proposed between this protein leak, which is maximal at seven days, and the development of right ventricular hypertrophy, which usually occurs 10-14 days after parenteral treatment.56 The same cardiovascular changes can, however, be induced with cumulative but smaller total doses of monocrotaline administered by the oral route.7 9 These regimens have produced a sequence of pulmonary circulatory changes that lead to pulmonary hypertension and right ventricular hyper-trophy,89 but more slowly than after single dose parenteral treatment. 6 9 Monocrotaline treatment produces various changes in the metabolic functions of the pulmonary circulation. 6 The average intake of monocrotaline solution was 21-1 (2-4) ml/rat/day, giving an average daily ingestion of 424 pg/rat/day.
ANATOMICAL DATA
The body weight was significantly reduced only after 28 days of monocrotaline treatment (table 1). The wet weight of the lung increased after three days of treatment, with a significant increase in lung to body weight ratio and parallel increases in total lung protein, dry weight, and water content that were significant after seven days' monocrotaline exposure (table 2) , although individual components did not change significantly as a proportion of total lung mass for any exposure period (table 2). Increase in lung mass was separated from the development of right ventricular hypertrophy, which occurred only after 15 days of monocrotaline treatment (tables I and 2). The accumulation of protein in the alveoli of rats treated with monocrotaline for seven or more days was presumed to be related to the presence of a microvascular protein leak.4 " Sugita et al5 induced a protein leak with a single parenteral dose (40 mg/kg) of monocrotaline. The leak was present after three days, preceded the development of right ventricular hypertrophy by 11 days, and was assumed to have a causal association. An increased permeability to protein was present throughout the 21 days of their study and the authors considered it possible that it was maintained by the raised pulmonary artery pressure. In the present study, however, protein accumulation in the alveolus was a sustained dose dependent effect of monocrotaline and was independent of the development of right ventricular hypertrophy, suggesting that the leak was unlikely to have been maintained by developing pulmonary hypertension. Sugita et al5 reported no effect on the alveoli of the leak they demonstrated, because albumin concentration was not raised one and three days after the start of monocrotaline ingestion. Inspection of their data, however, shows small but statistically significant increases in alveolar lavage albumin concentrations at one, seven, 14, and 21 days. Their data therefore are not at variance with our findings of protein accumulation in the alveoli after monocrotaline treatment, although they could not dissociate this from the later development of pulmonary hypertension and right ventricular hypertrophy.
We found differential changes in ACE activity between the circulatory, interstitial, and alveolar compartments of the lung, whereas previously only serum and lung activities have been reported. ACE is likely to have leaked passively into the alveolar space. The parallel change in protein concentration and ACE activity in lavage fluid and the correlation of L:S ratios for ACE and protein supports this. Similar changes in alveolar protein and ACE follow acute injury to the pulmonary endothelium of the rabbit by hyperoxia,16 but not after acute bacterial endotoxin injury in the mouse.17 Serum ACE activity may rise after acute endothelial injury as a result of release of enzyme into the circulation, with a corresponding fall in lung enzyme activity. 8 19This mechanism was not, however, active in this study as monocrotaline treatment did not cause a rise in serum ACE activity, except after 28 days' treatment, and the reduction of total lung ACE activity was maintained after monocrotaline treatment had ceased. Possibly the fall in ACE specific activity after seven or 15 days' treatment was due to addition of protein synthesised locally20 in response to monocrotaline induced alveolar injury.62'
The reduction of lung ACE activity after only three days of exposure to monocrotaline has not been reported previously. It implies an early direct effect of monocrotaline on the lung independent of the development of pulmonary hypertension.69 The sustained reduction ofenzyme activity in the lung may be due to several mechanisms. The most obvious explanation is that endothelial ACE content is unchanged and the reduction of ACE activity is apparent rather than real, because of inflammation and hyperplasia in the lung. The inverse correlation between lung dry weight and total or specific activity for lung ACE supports this. Other mechanisms, however, such as a reduction of the pulmonary circulatory surface area secondary to distal pulmonary vascular pruning, may occur after longer treatment periods.9 The reduced ability of the pulmonary vascular bed of the rat to generate 918 angiotensin II after monocrotaline treatment'1 also supports this interpretation, but is probably a longer term effect. Kay et al6 reported reduction of ACE activity 10 days after a single 60 mg/kg dose of monocrotaline, which coincided with a rise in pulmonary vascular resistance and preceded right ventricular hypertrophy. They suggested that this change represented a regulatory mechanism limiting the development of pulmonary hypertension.2 6 11 Our findings do not support this hypothesis as the ACE activity of the lung was consistently decreased at monocrotaline doses incapable of inducing right ventricular hypertrophy and preceding pulmonary hypertension.
Reduced lung ACE activity after monocrotaline ingestion confirms the findings of studies using single subcutaneous doses.2 610 This is at variance with the findings of other workers, who used the same strain of rats and a similar dosage schedule for monocrotaline.8 10 They used a microsomal extract of lung to determine ACE activity, and also argued that lung ACE could not be expressed in terms of protein as this changed in a non-uniform way with lung growth.°0 12 Inspection of their data shows that lung protein, water, and total weight increased in a proportionate manner.'0 Hence the lung protein was 0 148 and 0 146 mg/mg of lung for their control and monocrotaline groups, which is in keeping with our findings.
In summary, small cumulative doses of monocrotaline, incapable of inducing right ventricular hypertrophy, caused a sustained accumulation of protein in the alveolar spaces, increased lung mass, and reduced lung ACE activity. These effects were considered to be due to a dose dependent action of monocrotaline on the pulmonary circulation and the lung, and indicate that alveolar protein accumulation and changes in ACE activity are independent of the development of pulmonary hypertension under the circumstances of the experiments reported here.
